Giebel Sebastian, Miszczyk Leszek, Slosarek Krzysztof, Moukhtari Leila, Ciceri Fabio, Esteve Jordi, Gorin Norbert-Claude, Labopin Myriam, Nagler Arnon, Schmid Christoph, Mohty Mohamad
Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Cancer. 2014 Sep 1;120(17):2760-5. doi: 10.1002/cncr.28768. Epub 2014 May 7.
Total body irradiation (TBI) is widely used for conditioning before hematopoietic cell transplantation. Its efficacy and toxicity may depend on many methodological aspects. The goal of the current study was to explore current clinical practice in this field.
A questionnaire was sent to all centers collaborating in the European Group for Blood and Marrow Transplantation and included 19 questions regarding various aspects of TBI. A total of 56 centers from 23 countries responded.
All centers differed with regard to at least 1 answer. The total maximum dose of TBI used for myeloablative transplantation ranged from 8 grays (Gy) to 14.4 Gy, whereas the dose per fraction was 1.65 Gy to 8 Gy. A total of 16 dose/fractionation modalities were identified. The dose rate ranged from 2.25 centigrays to 37.5 centigrays per minute. The treatment unit was linear accelerator (LINAC) (91%) or cobalt unit (9%). Beams (photons) used for LINAC were reported to range from 6 to 25 megavolts. The most frequent technique used for irradiation was "patient in 1 field," in which 2 fields and 2 patient positions per fraction are used (64%). In 41% of centers, patients were immobilized during TBI. Approximately 93% of centers used in vivo dosimetry with accepted discrepancies between the planned and measured doses of 1.5% to 10%. In 84% of centers, the lungs were shielded during irradiation. The maximum accepted dose for the lungs was 6 Gy to 14.4 Gy.
TBI is an extremely heterogeneous treatment modality. The findings of the current study should warrant caution in the interpretation of clinical studies involving TBI. Further investigation is needed to evaluate how methodological differences influence outcome. Efforts to standardize the method should be considered.
全身照射(TBI)广泛应用于造血细胞移植前的预处理。其疗效和毒性可能取决于许多方法学方面。本研究的目的是探索该领域当前的临床实践。
向欧洲血液和骨髓移植协作组的所有中心发送了一份问卷,其中包括19个关于TBI各个方面的问题。来自23个国家的56个中心做出了回应。
所有中心至少在1个答案上存在差异。用于清髓性移植的TBI总最大剂量范围为8戈瑞(Gy)至14.4 Gy,而每次分割剂量为1.65 Gy至8 Gy。共确定了16种剂量/分割方式。剂量率范围为每分钟2.25厘戈瑞至37.5厘戈瑞。治疗设备为直线加速器(LINAC)(91%)或钴源装置(9%)。据报道,用于LINAC的射线(光子)能量范围为6至25兆伏。最常用的照射技术是“患者处于1个野”,即每次分割使用2个野和2个患者体位(64%)。在41%的中心,患者在TBI期间进行了固定。约93%的中心使用体内剂量测定法,计划剂量与测量剂量之间的可接受差异为1.5%至10%。在84%的中心,照射期间对肺部进行了屏蔽。肺部的最大可接受剂量为6 Gy至14.4 Gy。
TBI是一种极其异质性的治疗方式。本研究结果应提醒在解释涉及TBI的临床研究时要谨慎。需要进一步研究以评估方法学差异如何影响结局。应考虑努力使方法标准化。